Integrated genomic/epigenomic and proteomic/glycoproteomic analysis of Indolent vs. Aggressive prostate cancer

Using the independent but inter-related cohorts of aggressive vs. indolent prostate cancer developed at MCL sites Johns Hopkins and Stanford, the collaborative team will test if genetically and epigenetically encoded alterations in gene expression and protein expression/glycosylation can differentiate between indolent and aggressive cancer across both cohorts. The integrative approach will provide the most comprehensive information to date in understanding alterations in DNA -> RNA -> Proteins -> posttranslational modifications in aggressive vs. indolent prostate cancer